Starpharma Holdings Limited

As of June 30, 2026, Starpharma Holdings Limited carries a market capitalization of 179.32M, placing it among publicly traded companies globally. Its enterprise value stands at 173.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Starpharma Holdings Limited's next confirmed earnings release is scheduled for March 2, 2027.

As of June 30, 2026, Starpharma Holdings Limited has 432.07M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 24.50, and the price-to-book ratio stands at 21.49.

These figures are as of June 30, 2026. The EV/Sales ratio of 23.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 173.07M versus a market cap of 179.32M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Starpharma Holdings Limited maintains a current ratio of 3.40, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Starpharma Holdings Limited posted a negative return on equity (ROE) of -45.55, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.60, reflecting losses generated across the asset base. The company generates approximately 145,984.29 in revenue per employee across its workforce of 50.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.42 indicates how many times Starpharma Holdings Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Starpharma Holdings Limited's stock has gained approximately 84.52% over the past 52 weeks. The 50-day moving average sits at 0.46, while the 200-day moving average is 0.37.

Over the twelve months ended June 30, 2026, Starpharma Holdings Limited generated 7.30M in revenue and converted that into -4.52M in net income, yielding earnings per share of -0.01. EBITDA reached -4.90M, while operating income came in at -5.45M.

As of June 30, 2026, Starpharma Holdings Limited holds 6.67M in cash and equivalents against 428,260.97 in total debt, resulting in a net debt position of -6.45M. Total book value stands at 8.34M, with working capital of 7.52M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Starpharma Holdings Limited posted a gross margin of 93.82, reflecting its pricing power and cost economics. The operating margin of -74.64 and net profit margin of -61.95 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield reaches 0.30, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Starpharma Holdings Limited shareholders.

Starpharma Holdings Limited's most recent stock split took place on July 17, 2026 with a 340:349 split ratio.

As of June 30, 2026, Starpharma Holdings Limited has an Altman Z-Score of 14.62, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.